Janney Montgomery Scott Upgrades Sarepta Therapeutic (SRPT) to Buy
- Top 10 News for 10/24 - 10/28: AT&T (T), Time Warner Make it Official; Margins Hamper Apple's Q4; Mergers Aplenty
- Wall St stumbles as FBI to review more Clinton emails
- FBI to review more emails related to Clinton's private email use
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Janney Montgomery Scott upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Buy with a price target of $65.00.
Shares of Sarepta Therapeutic closed at $28.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Aetna (AET) Adds Sarepta's (NASDAQ: SRPT) Exondys 51 to Coverage List; Will be Effective Nov. 1st
- Stifel Upgrades Hub Group (HUBG) to Buy
- FBR Capital Upgrades Alexion Pharmaceuticals (ALXN) to Market Perform
Create E-mail Alert Related CategoriesUpgrades
Related EntitiesJanney Montgomery Scott
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!